Cytokine & Growth Factor Reviews
Volume 21, Issue 2 , Pages 91-98 , April 2010

Clinical trials with oncolytic reovirus: Moving beyond phase I into combinations with standard therapeutics

  • K.J. Harrington

      Affiliations

    • The Institute of Cancer Research, Chester Beatty Laboratories, Targeted Therapy Laboratory, 237 Fulham Road, London SW3 6JB, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 020 7153 5157; fax: +44 020 7808 2235.
    • ,
  • R.G. Vile

      Affiliations

    • Molecular Medicine Program, Mayo Clinic, Rochester, MN, USA
    • ,
  • A. Melcher

      Affiliations

    • Leeds Institute of Molecular Medicine, Leeds, UK
    • ,
  • J. Chester

      Affiliations

    • Leeds Institute of Molecular Medicine, Leeds, UK
    • ,
  • H.S. Pandha

      Affiliations

    • The University of Surrey, Guildford, UK

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S1359-6101(10)00017-1

doi: 10.1016/j.cytogfr.2010.02.006

Cytokine & Growth Factor Reviews
Volume 21, Issue 2 , Pages 91-98 , April 2010

Article Tools

* Image Usage & Resolution